EHA co-authors policy paper on drug repurposing
EHA has joined forces with other stakeholders such as the European Cancer Organisation, EORTC, and more, to author a policy paper on drug repurposing. This topic is one of the focuses of EHA in the revision of the EU’s pharmaceutical legislation, currently underway.
Article 48 of the proposed EU pharmaceutical regulation could have a transformative effect. The provision allows non-clinical and clinical evidence submissions by non-profit organizations to regulators, on new uses of authorized medicines and provides a pathway to label change. This in turn will facilitate integration of the new use into medical guidelines and reimbursement schemes, enhancing and accelerating the adoption of innovative treatments with clear patient benefit into clinical practice. The paper states that this provision creates a promising complementary path for generating patient benefit and public health impact, that could lead to faster and more cost-effective medical innovation and deliver more affordable treatments.
Read the policy paper on drug repurposing.
Back